Burke PJ - Search Results

1

Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.

Gore SD, Weng LJ, Jones RJ, Cowan K, Zilcha M, Piantadosi S, Burke PJ. Gore SD, et al. Among authors: burke pj. Clin Cancer Res. 1995 Mar;1(3):295-303. Clin Cancer Res. 1995. PMID: 9815985 Clinical Trial.

2

Validation of flow-cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia.

Gore SD, Weng LJ, Burke PJ. Gore SD, et al. Among authors: burke pj. Exp Hematol. 1993 Dec;21(13):1702-8. Exp Hematol. 1993. PMID: 7694870

3

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH. Rowinsky EK, et al. Among authors: burke pj. J Clin Oncol. 1994 Oct;12(10):2193-203. doi: 10.1200/JCO.1994.12.10.2193. J Clin Oncol. 1994. PMID: 7931489 Clinical Trial.

4

Identification of growth factor-responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation.

Gore SD, Weng LJ, Burke PJ. Gore SD, et al. Among authors: burke pj. Leukemia. 1994 Nov;8(11):1854-63. Leukemia. 1994. PMID: 7967731

5

Granulocyte-macrophage colony-stimulating factor (GM-CSF), given concurrently with induction therapy for acute myelogenous leukemia (AML), augments the syndrome of T-lymphocyte recovery.

Gore SD, Donnenberg AD, Zehnbauer BA, Weng LJ, Burke PJ. Gore SD, et al. Among authors: burke pj. Leukemia. 1994 Mar;8(3):409-19. Leukemia. 1994. PMID: 8127146 Clinical Trial.

6

Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.

Gore SD, Burke PJ, Weng LJ. Gore SD, et al. Among authors: burke pj. Leuk Lymphoma. 1998 Apr;29(3-4):339-50. doi: 10.3109/10428199809068570. Leuk Lymphoma. 1998. PMID: 9684931

7

Inhibited apoptosis and drug resistance in acute myeloid leukaemia.

Smith BD, Bambach BJ, Vala MS, Barber JP, Enger C, Brodsky RA, Burke PJ, Gore SD, Jones RJ. Smith BD, et al. Among authors: burke pj. Br J Haematol. 1998 Sep;102(4):1042-9. doi: 10.1046/j.1365-2141.1998.00854.x. Br J Haematol. 1998. PMID: 9734656 Free article.

8

A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.

Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M, Donehower RC, Burks KL, Armstrong DK, Burke PJ, Grever MR, Kaufmann SH. Gore SD, et al. Among authors: burke pj. Clin Cancer Res. 1998 Nov;4(11):2677-89. Clin Cancer Res. 1998. PMID: 9829730 Clinical Trial.

9

Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

Sotomayor EM, Piantadosi S, Miller CB, Karp JE, Jones RJ, Rowley SD, Kaufmann SH, Braine H, Burke PJ, Gore SD. Sotomayor EM, et al. Among authors: burke pj. Leuk Res. 2002 May;26(5):461-71. doi: 10.1016/s0145-2126(01)00175-8. Leuk Res. 2002. PMID: 11916520

10

Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.

Rowinsky EK, Donehower RC, Spivak JL, Burke PJ, Griffin CA, Jones RJ. Rowinsky EK, et al. Among authors: burke pj. J Natl Cancer Inst. 1990 Dec 19;82(24):1926-31. doi: 10.1093/jnci/82.24.1926. J Natl Cancer Inst. 1990. PMID: 2250314

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260 results

Search Page

Filters